Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway

Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway

Diabetic nephropathy (DN) is a microvascular complication of diabetes mellitus. This study examined the therapeutic effects of sitagliptin, a dipeptidyl peptidase inhibitor, on DN and explored the underlying mechanism. Male Wistar albino rats (<i>n</i> = 12) were intraperitoneally admini...

Full description

Bibliographic Details
Main Authors:	Sarah M. AL-Qabbaa, Samaher I. Qaboli, Tahani K. Alshammari, Maha A. Alamin, Haya M. Alrajeh, Lama A. Almuthnabi, Rana R. Alotaibi, Asma S. Alonazi, Anfal F. Bin Dayel, Nawal M. Alrasheed, Nouf M. Alrasheed
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	International Journal of Molecular Sciences
Subjects:	diabetic nephropathy Janus kinase/signal transducer activator of transcription pathway protein tyrosine phosphatase 1B inflammation
Online Access:	https://www.mdpi.com/1422-0067/24/7/6532

Similar Items

Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus
by: Shatha M. Alobaid, et al.
Published: (2024-03-01)

α1A Adrenoreceptor blockade attenuates myocardial infarction by modulating the integrin-linked kinase/TGF-β/Smad signaling pathways
by: Nawal M. Alrasheed, et al.
Published: (2023-03-01)

Examining the Indirect Effect of Online Gaming on Depression via Sleep Inequality and Anxiety—A Serial and Parallel Mediation Analysis
by: Tahani Alshammari, et al.
Published: (2022-12-01)

Inflammation and Treatment-Resistant Depression from Clinical to Animal Study: A Possible Link?
by: Lara F. Almutabagani, et al.
Published: (2023-01-01)

Examining anxiety and stress regarding virtual learning in colleges of health sciences: A cross-sectional study in the era of the COVID-19 pandemic in Saudi Arabia
by: Tahani Alshammari, et al.
Published: (2022-03-01)

Study on Synergistic Effect of Bromocriptine and Sitagliptin in Streptozotocin-induced Diabetic Rats
by: Govindaraj Nileshraj, et al.
Published: (2021-04-01)

Development of Janus Particles as Potential Drug Delivery Systems for Diabetes Treatment and Antimicrobial Applications
by: Kei Xian Tan, et al.
Published: (2023-01-01)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes - A renoprotective effect of sitagliptin
Published: (2021-01-01)

Microglia and Brain Macrophages as Drivers of Glioma Progression
by: Yuqi Zheng, et al.
Published: (2022-12-01)

Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms
by: Qamraa H. Alqahtani, et al.
Published: (2023-12-01)

Efficacy of baricitinib in severe coronavirus disease 2019
by: Ahmed M A E F Amer, et al.
Published: (2023-01-01)

Janus kinase inhibitors: between prescription authorization and reimbursability
by: F.R. Spinelli, et al.
Published: (2023-12-01)

Inhibidores de Janus Quinasas, consideraciones actuales
by: Sara Viviana Vargas López
Published: (2022-06-01)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
by: Jacopo Angelini, et al.
Published: (2020-07-01)

Thiolated Janus Silsesquioxane Tetrapod: New Precursors for Functional Materials
by: Mathilde Laird, et al.
Published: (2022-11-01)

Investigating Behavioral and Neuronal Changes in Adolescent Mice Following Prenatal Exposure to Electronic Cigarette (E-Cigarette) Vapor Containing Nicotine
by: Alaa AlHarthi, et al.
Published: (2023-10-01)

Selective reversible JAK1 inhibitor in the treatment of moderate and severe atopic dermatitis
by: Yu. S. Kovaleva, et al.
Published: (2022-03-01)

Correspondence on sitagliptin and cardiovascular outcomes in type 2 diabetes
by: Holman, R, et al.
Published: (2015)

HYPOGLYCEMIC EFFECT OF SITAGLIPTIN AND AMINOGUANIDINE COMBINATION IN EXPERIMENTAL DIABETES MELLITUS
by: D. V. Kurkin, et al.
Published: (2023-02-01)

Co-administration of metformin and gallic acid modulates JAK/STAT signaling pathway and glutathione metabolism in fructose-fed streptozotocin diabetic Rats
by: Olusola Olalekan Elekofehinti, et al.
Published: (2022-02-01)

Janus Particles: 1- Design and Preparation
by: Maede Ramezanpour, et al.
Published: (2022-08-01)

Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2
by: Zhenghui Song, et al.
Published: (2022-04-01)

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
by: Cristina Martinez-Molina, et al.
Published: (2024-02-01)

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
by: Srdan Verstovsek, et al.
Published: (2017-02-01)

Antidiabetic Effects of Aloe Vera Whole Leaf Extract and Sitagliptin in Streptozotocin-induced Diabetic Rats
by: Sobia Javaid, et al.
Published: (2020-12-01)

Evaluation of the role of CDKN2B gene in type 2 diabetes mellitus and hypertension in ethnic Saudi Arabs
by: Maha Meshal AlRasheed
Published: (2018-12-01)

Effect of ruxolitinib supplementation in enhancing neurogenesis via gliogenesis suppression in foetal mouse brain development
by: Hamzah, Hamizun
Published: (2019)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
by: Sylwia Słuczanowska-Głąbowska, et al.
Published: (2021-09-01)

Sr doped TiO2 photocatalyst for the removal of Janus Green B dye under visible light
by: Keerthana, Subramanian P., et al.
Published: (2024)

Mechanistic formation of drug-encapsulated Janus particles through emulsion solvent evaporation
by: Fan, Yan Liang, et al.
Published: (2019)

Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation,
by: Melpone Komnitski, et al.
Published: (2020-08-01)

The Potential Application of Pickering Multiple Emulsions in Food
by: Iveta Klojdová, et al.
Published: (2022-05-01)

Janus Kinase inhibitors in dermatology: a review
by: Bárbara Vieira-Granja, et al.
Published: (2023-01-01)

A Review on Fabrication of Janus Nanofibers through Side-by-Side Electrospinning Method
by: Mahdi Nouri, et al.
Published: (2022-05-01)

Cardioprotective Effects of the GRK2 Inhibitor Paroxetine on Isoproterenol-Induced Cardiac Remodeling by Modulating NF-κB Mediated Prohypertrophic and Profibrotic Gene Expression
by: Asma S. Alonazi, et al.
Published: (2023-12-01)

Sitagliptin and cardiovascular outcomes in type 2 diabetes - author's reply
by: Holman, RR, et al.
Published: (2015)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
by: Shannon A Miller, et al.
Published: (2009-05-01)

The durability of sitagliptin in elderly patients with type 2 diabetes
by: Hsieh CJ, et al.
Published: (2014-11-01)

Optimization of Thiolated Chitosan Nanoparticles for the Enhancement of in Vivo Hypoglycemic Efficacy of Sitagliptin in Streptozotocin-Induced Diabetic Rats
by: Kousalya Prabahar, et al.
Published: (2020-03-01)

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
by: Suvanjaa Sivalingam, et al.
Published: (2021-05-01)